Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

White-matter changes on MRI as surrogate marker.

Philip Scheltens1, Frederik Barkhof, Franz Fazekas

  • 1Department of Neurology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands. p.scheltens@vumc.nl

International Psychogeriatrics
|September 30, 2005
PubMed
Summary

White-matter changes on MRI are not yet reliable surrogate markers for vascular dementia clinical trials. Current methods lack sensitivity and have high measurement error, limiting their use in assessing treatment effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex Differences in Frequency, Severity, and Distribution of Cerebral Microbleeds.

JAMA network open·2024
Same author

European Academy of Neurology: First 10 years.

European journal of neurology·2024
Same author

Impact of Cerebral Microbleeds in Stroke Patients with Atrial Fibrillation.

Annals of neurology·2023
Same author

Ischemic Stroke 3 Months After Wrapping of an Incidental Aneurysm.

Stroke·2022
Same author

Incidence of Developmental Venous Anomalies in Patients With Multiple Sclerosis: A 3 Tesla MRI Study.

Frontiers in neurology·2022
Same author

Global Differences in Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults-A Worldwide Meta-analysis: The GOAL Initiative.

Neurology·2021

Area of Science:

  • Neurology
  • Radiology
  • Clinical Trials

Background:

  • Vascular dementia is a significant cause of cognitive decline.
  • Magnetic Resonance Imaging (MRI) is frequently used in neurological research.
  • White-matter changes are common findings on MRI in elderly populations.

Purpose of the Study:

  • To review the utility of white-matter changes on MRI as a surrogate marker in clinical trials for vascular dementia.
  • To assess the current evidence supporting the use of white-matter changes in clinical trial design.

Main Methods:

  • Literature review of studies using MRI to assess white-matter changes in vascular dementia.
  • Analysis of the sensitivity to change and measurement error of current assessment methods for white-matter changes.

Related Experiment Videos

  • Evaluation of the suitability of white-matter changes as a surrogate endpoint in clinical trials.

    • Main Results:

    • Insufficient evidence currently supports the use of white-matter changes as a surrogate marker in vascular dementia trials.
    • Existing methods for rating or volumetric assessment of white-matter changes show limited sensitivity to change.
    • High measurement error associated with current methods further restricts their reliability.

    Conclusions:

    • White-matter changes on MRI are not yet validated as reliable surrogate markers for vascular dementia clinical trials.
    • Further research is needed to improve the sensitivity and reduce the measurement error of MRI-based assessments.
    • Current limitations preclude the implementation of white-matter changes as a standard surrogate marker in these trials.